News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Epilepsy Biotech Marinus Pharmaceuticals (MRNS) Prices IPO At $10/Share


7/31/2014 7:35:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Marinus Pharmaceuticals Announces Pricing Of Initial Public Offering

NEW HAVEN, Conn., July 31, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced the pricing of its initial public offering of 5,625,000 shares of its common stock at a public offering price of $8.00 per share, before underwriting discounts. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "MRNS" on July 31, 2014. In addition, Marinus has granted the underwriters a 30-day option to purchase up to an additional 843,750 shares of common stock at the same price to cover over-allotments, if any. The offering is expected to close on August 5, 2014, subject to customary closing conditions.

Stifel and JMP Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as lead manager and Janney Montgomery Scott is acting as co-manager for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 31, 2014. The offering will be made only by means of a prospectus, copies of which may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by calling (415) 364-2720 or by emailing SyndicateOps@stifel.com, and from JMP Securities LLC, Attention: Prospectus Department, 600 Montgomery St., 10th Floor, San Francisco, CA 94111, or by calling (415) 835-8985.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

CONTACT: Edward F. Smith Vice President, CFO, Secretary and Treasurer Marinus Pharmaceuticals, Inc. (203) 315-0566 esmith@marinuspharma.com

Marinus Pharmaceuticals logo



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES